TY - JOUR
T1 - MRI measurements of vessel calibre in tumour xenografts
T2 - Comparison with vascular corrosion casting
AU - Burrell, Jake S.
AU - Bradley, Robert S.
AU - Walker-Samuel, Simon
AU - Jamin, Yann
AU - Baker, Lauren C.J.
AU - Boult, Jessica K.R.
AU - Withers, Philip J.
AU - Halliday, Jane
AU - Waterton, John C.
AU - Robinson, Simon P.
PY - 2012/11
Y1 - 2012/11
N2 - Vessel size index (Rv, μm) has been proposed as a quantitative magnetic resonance imaging (MRI) derived imaging biomarker in oncology, for the non-invasive assessment of tumour blood vessel architecture and vascular targeted therapies. Appropriate pre-clinical evaluation of Rv in animal tumour models will improve the interpretation and guide the introduction of the biomarker into clinical studies. The objective of this study was to compare Rv measured in vivo with vessel size measurements from high-resolution X-ray computed tomography (μCT) of vascular corrosion casts measured post mortem from the same tumours, with and without vascular targeted therapy. MRI measurements were first acquired from subcutaneous SW1222 colorectal xenografts in mice following treatment with 0 (n=6), 30 (n=6) or 200mg/kg (n=3) of the vascular disrupting agent ZD6126. The mice were then immediately infused with a low viscosity resin and, following polymerisation and maceration of surrounding tissues, the resulting tumour vascular casts were dissected and subsequently imaged using an optimised μCT imaging approach. Vessel diameters were not measurable by μCT in the 200mg/kg group as the high dose of ZD6126 precluded delivery of the resin to the tumour vascular bed. The mean Rv for the three treatment groups was 24, 23 and 23.5μm respectively; the corresponding μCT measurements from corrosion casts from the 0 and 30mg/kg cohorts were 25 and 28μm. The strong association between the in vivo MRI and post mortem μCT values supports the use of Rv as an imaging biomarker in clinical trials of investigational vascular targeted therapies.
AB - Vessel size index (Rv, μm) has been proposed as a quantitative magnetic resonance imaging (MRI) derived imaging biomarker in oncology, for the non-invasive assessment of tumour blood vessel architecture and vascular targeted therapies. Appropriate pre-clinical evaluation of Rv in animal tumour models will improve the interpretation and guide the introduction of the biomarker into clinical studies. The objective of this study was to compare Rv measured in vivo with vessel size measurements from high-resolution X-ray computed tomography (μCT) of vascular corrosion casts measured post mortem from the same tumours, with and without vascular targeted therapy. MRI measurements were first acquired from subcutaneous SW1222 colorectal xenografts in mice following treatment with 0 (n=6), 30 (n=6) or 200mg/kg (n=3) of the vascular disrupting agent ZD6126. The mice were then immediately infused with a low viscosity resin and, following polymerisation and maceration of surrounding tissues, the resulting tumour vascular casts were dissected and subsequently imaged using an optimised μCT imaging approach. Vessel diameters were not measurable by μCT in the 200mg/kg group as the high dose of ZD6126 precluded delivery of the resin to the tumour vascular bed. The mean Rv for the three treatment groups was 24, 23 and 23.5μm respectively; the corresponding μCT measurements from corrosion casts from the 0 and 30mg/kg cohorts were 25 and 28μm. The strong association between the in vivo MRI and post mortem μCT values supports the use of Rv as an imaging biomarker in clinical trials of investigational vascular targeted therapies.
UR - https://www.scopus.com/pages/publications/84868108492
U2 - 10.1016/j.mvr.2012.08.001
DO - 10.1016/j.mvr.2012.08.001
M3 - Article
C2 - 22921880
AN - SCOPUS:84868108492
SN - 0026-2862
VL - 84
SP - 323
EP - 329
JO - Microvascular Research
JF - Microvascular Research
IS - 3
ER -